By John Vandermosten, CFA

CNSX:ORTH.CN | OTC:ORTIF

READ THE FULL ORTH.CN RESEARCH REPORT

Clinical Hold Letter Lifted

Following the April 2021 Investigational New Drug (IND) submission for Ortho-R, Ortho Regenerative Technologies Inc. (CSE:ORTH) (OTC:ORTIF) notified the public on December 13^ththat the FDA had lifted its Clinical Hold on the application. Two months after its IND submission, Ortho announced that a clinical hold had been placed on the trial launch pending the collection of additional chemistry, manufacturing and control (CMC) related data and characterization of the chitosan product. On July 20^th, Ortho announced that it...